Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04684017
Other study ID # KS2039
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2019
Est. completion date January 1, 2022

Study information

Verified date December 2019
Source Shanghai Chest Hospital
Contact Baohui Han
Phone +86 18930858216
Email 18930858216@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of etoposide and carboplatin (administered intravenously) in combination with anlotinib (administered orally) in treatment-naive advanced NSCLC.


Description:

Lung cancer can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which SCLC accounts for about 15%-20%.Because of the high degree of malignancy of SCLC, patients often lose the opportunity of surgical treatment due to metastasis at the time of admission. Traditional cytotoxic drugs can improve the prognosis of patients and life treatment, but the survival benefit is very limited. Vascular targeted therapy is an important treatment strategy for metastatic lung cancer.Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor that has significant inhibitory activity against angiogenesis related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor related kinases such as PDGFR /, C-Kit, Ret, etc. (e.g., Met, FGFR1/2/3). An exploratory phase II study explored the efficacy of third-line single-drug therapy for ED-SCLC and found significant improvement in prognosis. Based on the above status and research results, the purpose of this study was to explore the efficacy and safety of anlotinib hydrochloride combined with etoposide/carboplatin in first-line treatment of extensive small-cell lung cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 29
Est. completion date January 1, 2022
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with extensive stage SCLC confirmed by histology or cytology and are confirmed to have at least one measurable lesion according to RECIST 1.1. 2. Without active brain metastasis 3. Previously treated with ICIs with progressive disease. 4. Age =18 years and =75 years; 5. ECOG PS score: 0 to 1 6. The main organs function is normal, that is, the following criteria met: good hematopoietic function, defined as absolute neutrophil count =1.5×109 /L, platelet count=100 ×109 /L, hemoglobin =90g/L [no blood transfusion or no erythropoietin (EPO) dependence within 7 days before enrollment]; biochemical test results should meet the following criteria: BIL < 1.25 times the upper limit of normal value (ULN); ALT and AST < 2.5 × ULN; in case of liver metastases, ALT and AST < 5 × ULN; Cr =1.5×ULN or creatinine clearance (CCr) =60ml/min; Coagulation function is good, INR and PT =1.5 times ULN; if the subject is receiving anticoagulant treatment, PT should be within the prescribed range of use of anticoagulant drugs; 7. Women of child-bearing age should agree to take contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study and within 6 months after the study; non-breast-feeding patients whose serum or urinary pregnancy test should be negative; male patients should agree to take contraceptive measures during the study and within 6 months after the study. 8. Patients are voluntarily enrolled into the study, sign the informed consent form and have good compliance. Exclusion Criteria: 1. Subjects with active CNS metastases are excluded. 2. Non-small cell lung cancer. 3. With obvious hemorrhage symptom 4. Patients with many factors affecting oral medication, such as dysphagia, gastrointestinal resection, chronic diarrhea and intestinal obstruction. 5. Combined with other tumors at the time of initial diagnosis. 6. Patients who have previously participated in other clinical trials and have not yet terminated the trial. 7. Patients who have acute infection that difficult to control.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Anlotinib hydrochloride
anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
Etoposide
100mg/m2 iv on days 1-3 every 21 days for 4 cycles
Carboplatin
AUC 5 iv on day 1 every 21 days for 4 cycles

Locations

Country Name City State
China Shanghai Chest hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Chest Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS Time from enrollment to progression or death Time from randomization to progression, assessed 9-11 months
Secondary ORR Patients who were assessed as partial response or complete response 6-9 weeks
Secondary OS Time from enrollment to death of any cause 13-15 months
Secondary DCR Patients who were assessed as partial response, complete response or stable disease 6-9 weeks
See also
  Status Clinical Trial Phase
Completed NCT05026593 - A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05903092 - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT00046787 - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer Phase 2
Suspended NCT04826341 - A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Phase 1/Phase 2
Recruiting NCT05655598 - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Phase 1
Withdrawn NCT04677361 - Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab Early Phase 1
Terminated NCT00522639 - Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation Phase 3
Completed NCT03428607 - Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] Phase 2
Recruiting NCT05546268 - Study of Oral MRT-2359 in Selected Cancer Patients Phase 1/Phase 2
Recruiting NCT06116019 - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Not yet recruiting NCT03244904 - Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment N/A
Completed NCT01713296 - Pazopanib in Relapsed and Refractory Small Cell Lung Cancer Phase 2
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Recruiting NCT05130255 - GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 Phase 1
Recruiting NCT04686682 - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Recruiting NCT05879068 - A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC Phase 2
Completed NCT00346385 - BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT02734004 - A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Phase 1/Phase 2